Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Apr;84(8):1107–1114. doi: 10.1054/bjoc.2000.1713

N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours

M K Ranes 1, M El-Abbadi 1, M G Manfredi 1, P Mukherjee 1, F M Platt 2, T N Seyfried 1
PMCID: PMC2363859  PMID: 11308262

Abstract

Abnormalities in glycosphingolipid (GSL) biosynthesis have been implicated in the oncogenesis and malignancy of brain tumours. GSLs comprise the gangliosides and the neutral GSLs and are major components of the cell surface glycocalyx. N -butyldeoxynojirimycin (N B-DNJ) is an imino sugar that inhibits the glucosyltransferase catalysing the first step in GSL biosynthesis. The influence of N B-DNJ was studied on the growth and ganglioside composition of two 20-methylcholanthrene-induced experimental mouse brain tumours, EPEN and CT-2A, which were grown in vitro and in vivo. N B-DNJ (200 μM) inhibited the proliferation of the EPEN and CT-2A cells by 50%, but did not reduce cell viability. The drug, administered in the diet (2400 mg kg−1) to adult syngeneic C57BL/6 mice, reduced the growth and ganglioside content of subcutaneous and intracerebral EPEN and CT-2A tumours by at least 50% compared to the untreated controls. N B-DNJ treatment also shifted the relative distribution of tumour gangliosides in accordance with the depletion of metabolic substrates. Side effects of N B-DNJ treatment were generally mild and included reductions in body and spleen weights and intestinal distension. We conclude that N B-DNJ may inhibit tumour growth through an effect on ganglioside biosynthesis and may be useful as a new chemotherapy for brain tumours. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: glycosphingolipids, N-butyldeoxynojirimycin, glucosyltransferase, brain tumours, mouse, gangliosides, glioma

Full Text

The Full Text of this article is available as a PDF (288.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alessandri G., Cornaglia-Ferraris P., Gullino P. M. Angiogenic and angiostatic microenvironment in tumors--role of gangliosides. Acta Oncol. 1997;36(4):383–387. doi: 10.3109/02841869709001284. [DOI] [PubMed] [Google Scholar]
  2. Andersson U., Butters T. D., Dwek R. A., Platt F. M. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol. 2000 Apr 1;59(7):821–829. doi: 10.1016/s0006-2952(99)00384-6. [DOI] [PubMed] [Google Scholar]
  3. Bai H., Seyfried T. N. Influence of ganglioside GM3 and high density lipoprotein on the cohesion of mouse brain tumor cells. J Lipid Res. 1997 Jan;38(1):160–172. [PubMed] [Google Scholar]
  4. Berra B., Colombo I., Monteggia E., Montorfano G., Moretti S., Rapelli S., Sottocornola E. Glycosphingolipid expression in solid tumours and transformed cell lines. Indian J Biochem Biophys. 1997 Feb-Apr;34(1-2):170–177. [PubMed] [Google Scholar]
  5. Brigande J. V., Platt F. M., Seyfried T. N. Inhibition of glycosphingolipid biosynthesis does not impair growth or morphogenesis of the postimplantation mouse embryo. J Neurochem. 1998 Feb;70(2):871–882. doi: 10.1046/j.1471-4159.1998.70020871.x. [DOI] [PubMed] [Google Scholar]
  6. Chang F., Li R., Ladisch S. Shedding of gangliosides by human medulloblastoma cells. Exp Cell Res. 1997 Aug 1;234(2):341–346. doi: 10.1006/excr.1997.3619. [DOI] [PubMed] [Google Scholar]
  7. Cotterchio M., Seyfried T. N. Serum gangliosides in mice with metastatic and non-metastatic brain tumors. J Lipid Res. 1994 Jan;35(1):10–14. [PubMed] [Google Scholar]
  8. Cotterchio M., Seyfried T. N. The influence of ImuVert, a biological response modifier, on the growth and ganglioside composition of murine neural tumors. Mol Chem Neuropathol. 1993 Oct;20(2):163–172. doi: 10.1007/BF02815369. [DOI] [PubMed] [Google Scholar]
  9. Cox T., Lachmann R., Hollak C., Aerts J., van Weely S., Hrebícek M., Platt F., Butters T., Dwek R., Moyses C. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000 Apr 29;355(9214):1481–1485. doi: 10.1016/S0140-6736(00)02161-9. [DOI] [PubMed] [Google Scholar]
  10. Davis F. G., McCarthy B. J., Freels S., Kupelian V., Bondy M. L. The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer. 1999 Jan 15;85(2):485–491. [PubMed] [Google Scholar]
  11. Ecsedy J. A., Holthaus K. A., Yohe H. C., Seyfried T. N. Expression of mouse sialic acid on gangliosides of a human glioma grown as a xenograft in SCID mice. J Neurochem. 1999 Jul;73(1):254–259. doi: 10.1046/j.1471-4159.1999.0730254.x. [DOI] [PubMed] [Google Scholar]
  12. Ecsedy J. A., Yohe H. C., Bergeron A. J., Seyfried T. N. Tumor-infiltrating macrophages influence the glycosphingolipid composition of murine brain tumors. J Lipid Res. 1998 Nov;39(11):2218–2227. [PubMed] [Google Scholar]
  13. FOLCH J., LEES M., SLOANE STANLEY G. H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497–509. [PubMed] [Google Scholar]
  14. Fathallah-Shaykh H. New molecular strategies to cure brain tumors. Arch Neurol. 1999 Apr;56(4):449–453. doi: 10.1001/archneur.56.4.449. [DOI] [PubMed] [Google Scholar]
  15. Fischl M. A., Resnick L., Coombs R., Kremer A. B., Pottage J. C., Jr, Fass R. J., Fife K. H., Powderly W. G., Collier A. C., Aspinall R. L. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr. 1994 Feb;7(2):139–147. [PubMed] [Google Scholar]
  16. Flavin H. J., Wieraszko A., Seyfried T. N. Enhanced aspartate release from hippocampal slices of epileptic (El) mice. J Neurochem. 1991 Mar;56(3):1007–1011. doi: 10.1111/j.1471-4159.1991.tb02021.x. [DOI] [PubMed] [Google Scholar]
  17. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996 Dec 1;56(23):5309–5318. [PubMed] [Google Scholar]
  18. Harbaugh K. S., Black P. M. Strategies in the surgical management of malignant gliomas. Semin Surg Oncol. 1998 Jan-Feb;14(1):26–33. doi: 10.1002/(sici)1098-2388(199801/02)14:1<26::aid-ssu4>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  19. Jeyakumar M., Butters T. D., Cortina-Borja M., Hunnam V., Proia R. L., Perry V. H., Dwek R. A., Platt F. M. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6388–6393. doi: 10.1073/pnas.96.11.6388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Karlsson G. B., Butters T. D., Dwek R. A., Platt F. M. Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120. J Biol Chem. 1993 Jan 5;268(1):570–576. [PubMed] [Google Scholar]
  21. Kemp R. B. Effect of the removal of cell surface sialic acids on cell aggregation in vitro. Nature. 1968 Jun 29;218(5148):1255–1256. doi: 10.1038/2181255a0. [DOI] [PubMed] [Google Scholar]
  22. Liu Y. Y., Han T. Y., Giuliano A. E., Cabot M. C. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem. 1999 Jan 8;274(2):1140–1146. doi: 10.1074/jbc.274.2.1140. [DOI] [PubMed] [Google Scholar]
  23. Manfredi M. G., Lim S., Claffey K. P., Seyfried T. N. Gangliosides influence angiogenesis in an experimental mouse brain tumor. Cancer Res. 1999 Oct 15;59(20):5392–5397. [PubMed] [Google Scholar]
  24. Merzak A., Koochekpour S., McCrea S., Roxanis Y., Pilkington G. J. Gangliosides modulate proliferation, migration, and invasiveness of human brain tumor cells in vitro. Mol Chem Neuropathol. 1995 Feb-Apr;24(2-3):121–135. doi: 10.1007/BF02962138. [DOI] [PubMed] [Google Scholar]
  25. Platt F. M., Butters T. D. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem Pharmacol. 1998 Aug 15;56(4):421–430. doi: 10.1016/s0006-2952(98)00115-4. [DOI] [PubMed] [Google Scholar]
  26. Platt F. M., Neises G. R., Dwek R. A., Butters T. D. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994 Mar 18;269(11):8362–8365. [PubMed] [Google Scholar]
  27. Platt F. M., Neises G. R., Reinkensmeier G., Townsend M. J., Perry V. H., Proia R. L., Winchester B., Dwek R. A., Butters T. D. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 1997 Apr 18;276(5311):428–431. doi: 10.1126/science.276.5311.428. [DOI] [PubMed] [Google Scholar]
  28. Platt F. M., Reinkensmeier G., Dwek R. A., Butters T. D. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J Biol Chem. 1997 Aug 1;272(31):19365–19372. doi: 10.1074/jbc.272.31.19365. [DOI] [PubMed] [Google Scholar]
  29. Prados M. D., Levin V. Biology and treatment of malignant glioma. Semin Oncol. 2000 Jun;27(3 Suppl 6):1–10. [PubMed] [Google Scholar]
  30. Radin N. S. Chemotherapy by slowing glucosphingolipid synthesis. Biochem Pharmacol. 1999 Mar 15;57(6):589–595. doi: 10.1016/s0006-2952(98)00274-3. [DOI] [PubMed] [Google Scholar]
  31. SVENNERHOLM L. Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta. 1957 Jun;24(3):604–611. doi: 10.1016/0006-3002(57)90254-8. [DOI] [PubMed] [Google Scholar]
  32. Sandhoff K., van Echten G. Ganglioside metabolism: enzymology, topology and regulation. Prog Brain Res. 1994;101:17–29. doi: 10.1016/s0079-6123(08)61937-8. [DOI] [PubMed] [Google Scholar]
  33. Schmidt C. W. Childhood cancer: A growing problem. Environ Health Perspect. 1998 Jan;106(1):A18–A23. doi: 10.1289/ehp.98106a18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Seyfried T. N., Glaser G. H., Yu R. K. Cerebral, cerebellar, and brain stem gangliosides in mice susceptible to audiogenic seizures. J Neurochem. 1978 Jul;31(1):21–27. doi: 10.1111/j.1471-4159.1978.tb12428.x. [DOI] [PubMed] [Google Scholar]
  35. Seyfried T. N., Novikov A. M., Irvine R. A., Brigande J. V. Ganglioside biosynthesis in mouse embryos: sialyltransferase IV and the asialo pathway. J Lipid Res. 1994 Jun;35(6):993–1001. [PubMed] [Google Scholar]
  36. Seyfried T. N., Yu R. K., Saito M., Albert M. Ganglioside composition of an experimental mouse brain tumor. Cancer Res. 1987 Jul 1;47(13):3538–3542. [PubMed] [Google Scholar]
  37. Seyfried T. N., el-Abbadi M., Ecsedy J. A., Bai H. W., Yohe H. C. Influence of host cell infiltration on the glycolipid content of mouse brain tumors. J Neurochem. 1996 May;66(5):2026–2033. doi: 10.1046/j.1471-4159.1996.66052026.x. [DOI] [PubMed] [Google Scholar]
  38. Seyfried T. N., el-Abbadi M., Ecsedy J. A., Griffin M. E., Yohe H. C. Ganglioside composition of a mouse brain tumor grown in the severe combined immunodeficiency (SCID) mouse. Mol Chem Neuropathol. 1998 Jan;33(1):27–37. doi: 10.1007/BF02815857. [DOI] [PubMed] [Google Scholar]
  39. Seyfried T. N., el-Abbadi M., Roy M. L. Ganglioside distribution in murine neural tumors. Mol Chem Neuropathol. 1992 Oct;17(2):147–167. doi: 10.1007/BF03159989. [DOI] [PubMed] [Google Scholar]
  40. Shapiro W. R. Current therapy for brain tumors: back to the future. Arch Neurol. 1999 Apr;56(4):429–432. doi: 10.1001/archneur.56.4.429. [DOI] [PubMed] [Google Scholar]
  41. Yung W. K., Albright R. E., Olson J., Fredericks R., Fink K., Prados M. D., Brada M., Spence A., Hohl R. J., Shapiro W. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000 Sep;83(5):588–593. doi: 10.1054/bjoc.2000.1316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Zeng G., Gao L., Birklé S., Yu R. K. Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res. 2000 Dec 1;60(23):6670–6676. [PubMed] [Google Scholar]
  43. Zimmerman H. M. Production of brain tumors with aromatic hydrocarbons. Ann N Y Acad Sci. 1982;381:320–324. doi: 10.1111/j.1749-6632.1982.tb50395.x. [DOI] [PubMed] [Google Scholar]
  44. el-Abbadi M., Seyfried T. N. Influence of growth environment on the ganglioside composition of an experimental mouse brain tumor. Mol Chem Neuropathol. 1994 Feb-Apr;21(2-3):273–285. doi: 10.1007/BF02815355. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES